The methotrexate story: a paradigm for development of cancer chemotherapeutic agents.

Methotrexate (MTX), one of the earliest cancer chemotherapy agents, continues to be used extensively in the treatment of leukemia and a variety of other tumors. The efficacy of this drug results from its facile uptake by cells, rapid polyglutamylation and virtually stoichiometric inhibition of dihydrofolate reductase (DHFR), a key enzyme in cell replication. From the work of a multitude of biochemists, molecular biologists, organic chemists and pharmacologists, much is known about the mode of action of MTX and the mechanisms by which tumors exhibit inherent or acquired resistance to this drug. MTX enters cells primarily by a carrier-mediated active transport system whose principal substrate is 5-methyltetrahydrofolate, and additional glutamates are added to the gamma-position of the parent glutamate moiety. The tight binding of MTX to DHFR is defined from NMR and X-ray crystallographic studies of the enzyme and its drug or substrate complexes, supplemented by site-directed mutagenesis to confirm specific interactions. Resistance to the drug, encountered in cell culture model systems or in cancer patients, can result from an increased level of DHFR (due to gene amplification), mutant DHFR with reduced affinity for MTX, or decreased uptake or polyglutamylation of the drug. Although DHFR is an extremely well-studied enzyme, there is still some uncertainty about its kinetics, mechanism for reduction of folate, multiple forms, and activation by a diverse group of agents. Prodrug forms of MTX, e.g., MTX alpha-phenylalanine, which can be activated by carboxypeptidase A-monoclonal antibody conjugates, offer promise for improved efficacy of the drug by selective targeting to tumors. The large body of information summarized above has aided in the development of other folate antagonists, provides a paradigm for assessing the status of other cancer chemotherapeutic agents in current use, and offers a platform from which to speculate about the future of the field.

[1]  F. Sirotnak,et al.  10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties. , 1987, NCI monographs : a publication of the National Cancer Institute.

[2]  G. Hitchings,et al.  Inhibitor binding analysis of dihydrofolate reductases from various species. , 1965, Molecular pharmacology.

[3]  F. M. Huennekens,et al.  Multiple folate transport systems in L1210 cells. , 1992, Advances in enzyme regulation.

[4]  F. M. Huennekens,et al.  Vitamin B12-dependent replication of L1210 mouse leukemia cells. A model system for cobalamin-folate inter-relationships. , 1981, The Journal of biological chemistry.

[5]  F. M. Huennekens,et al.  Thymidylate synthetase from amethopterin-resistant Lactobacillus casei. , 1971, Biochemistry.

[6]  F. M. Huennekens,et al.  Biochemistry of Methotrexate: Teaching an Old Drug New Tricks , 1987 .

[7]  S. Benkovic,et al.  On interpreting the inhibition of and catalysis by dihydrofolate reductase , 1987 .

[8]  C. A. Nichol,et al.  On the enzymic reduction of folic acid by a purified hydrogenase. , 1958, Biochimica et biophysica acta.

[9]  J. Gready.  Dihydrofolate reductase: binding of substrates and inhibitors and catalytic mechanism. , 1980, Advances in pharmacology and chemotherapy.

[10]  R. G. Anderson,et al.  Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol. , 1989, The Journal of clinical investigation.

[11]  F. M. Huennekens,et al.  Biotin derivatives of methotrexate and folate. Synthesis and utilization for affinity purification of two membrane-associated folate transporters from L1210 cells. , 1991, The Journal of biological chemistry.

[12]  R. Hertz,et al.  Effect of Methotrexate Therapy upon Choriocarcinoma and Chorioadenoma , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[13]  M. Kris,et al.  Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Matherly,et al.  The cellular pharmacology of methotrexate. , 1985, Pharmacology & therapeutics.

[15]  W. Foulkes,et al.  Folate-binding protein is a marker for ovarian cancer. , 1991, Cancer research.

[16]  M. Hakala,et al.  Relation of folic acid reductase to amethopterin resistance in cultured mammalian cells. , 1961, The Journal of biological chemistry.

[17]  F. M. Huennekens,et al.  Enzymatic reduction of dihydrofolic acid. , 1958, The Journal of biological chemistry.

[18]  C. Baugh,et al.  NATURALLY OCCURRING FOLATES * , 1971, Annals of the New York Academy of Sciences.

[19]  J. Schornagel,et al.  Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. , 1991, Cancer research.

[20]  E. Price,et al.  Photoaffinity analogues of methotrexate as folate antagonist binding probes. 2. Transport studies, photoaffinity labeling, and identification of the membrane carrier protein for methotrexate from murine L1210 cells. , 1987, Biochemistry.

[21]  F. M. Huennekens,et al.  Dihydrofolate reductase from amethopterin-resistant Lactobacillus casei. , 1972, Biochemistry.

[22]  S. Futterman.  Enzymatic reduction of folic acid and dihydrofolic acid to tetrahydrofolic acid. , 1957, The Journal of biological chemistry.

[23]  F. M. Huennekens,et al.  TPNH-dependent binding of amethopterin by dihydrofolate reductase from Lactobacillus casei. , 1972, Archives of biochemistry and biophysics.

[24]  R. Schimke,et al.  Gene amplification in a single cell cycle in Chinese hamster ovary cells. , 1984, The Journal of biological chemistry.

[25]  F. M. Huennekens,et al.  Substrate and inhibitor complexes of dihydrofolate reductase from amethopterin-resistant L1210 cells. , 1975, Archives of biochemistry and biophysics.

[26]  P. Elwood,et al.  The isolation, characterization, and comparison of the membrane-associated and soluble folate-binding proteins from human KB cells. , 1986, The Journal of biological chemistry.

[27]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[28]  F. M. Huennekens,et al.  Cyclic adenosine 3':5'-monophosphate and methotrexate transport in L1210 cells. , 1978, Cancer research.

[29]  S. Smith,et al.  Dihydrofolate reductases as targets for inhibitors. , 1980, Advances in enzyme regulation.

[30]  C. Hansch,et al.  Crystal structure of avian dihydrofolate reductase containing phenyltriazine and NADPH. , 1982, The Journal of biological chemistry.

[31]  C. Mathews,et al.  Spectral changes associated with binding of folate compounds to bacteriophage T4 dihydrofolate reductase. , 1972, Journal of Biological Chemistry.

[32]  F. M. Huennekens,et al.  Dihydrofolate Reductases: Structural and Mechanistic Aspects * , 1971, Annals of the New York Academy of Sciences.

[33]  I. Judson,et al.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. , 1991, Cancer research.

[34]  J. Bertino,et al.  Karnofsky memorial lecture. Ode to methotrexate. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. M. Buchanan,et al.  The utilization of formate in uric acid synthesis. , 1946, The Journal of biological chemistry.

[36]  R. G. Anderson,et al.  Potocytosis: sequestration and transport of small molecules by caveolae. , 1992, Science.

[37]  J M Burridge,et al.  Dihydrofolate reductase. The stereochemistry of inhibitor selectivity. , 1985, The Journal of biological chemistry.

[38]  J. Bolin,et al.  Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. II. Environment of bound NADPH and implications for catalysis. , 1982, The Journal of biological chemistry.

[39]  F. M. Huennekens,et al.  Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate. , 1992, Biochemistry.

[40]  A. Goldin,et al.  Increased Dihydrofolate Reductase Activity as a Possible Basis of Drug Resistance in Leukæmia , 1961, Nature.

[41]  L R Coney,et al.  Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. , 1992, Cancer research.

[42]  F. M. Huennekens,et al.  Membrane transport of folate compounds. , 1992, Journal of Nutritional Science and Vitaminology.

[43]  Fischer Ga.  Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemic cells. , 1961 .

[44]  F. M. Huennekens,et al.  Affinity labeling of folate transport proteins with the N-hydroxysuccinimide ester of the gamma-isomer of fluorescein-methotrexate. , 1991, Biochemistry.

[45]  J. Bertino,et al.  Design and rationale for novel antifolates. , 1987, NCI monographs : a publication of the National Cancer Institute.

[46]  J. Bertino,et al.  Quantitation of dihydrofolate reductase in individual parental and methotrexate-resistant murine cells. Use of a fluorescence activated cell sorter. , 1978, The Journal of biological chemistry.

[47]  C. A. Nichol,et al.  Water-soluble vitamins concerned with one and two-carbon intermediates. , 1952, Annual review of biochemistry.

[48]  M. Hultquist,et al.  Analogs of Pteroylglutamic Acid. III. 4-Amino Derivatives , 1949 .

[49]  G. R. Greenberg.  A FORMYLATION COFACTOR1 , 1954 .

[50]  I. Wilson,et al.  Crystal structure of glycinamide ribonucleotide transformylase from Escherichia coli at 3.0 A resolution. A target enzyme for chemotherapy. , 1992, Journal of molecular biology.

[51]  R M Stroud,et al.  Atomic structure of thymidylate synthase: target for rational drug design. , 1987, Science.

[52]  J. Bertino.  Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture. , 1979, Cancer research.

[53]  F. M. Huennekens,et al.  Purification of dihydrofolate reductase via amethopterin-aminoethyl starch. , 1968, The Journal of biological chemistry.

[54]  P. Senter.  Activation of prodrugs by antibody‐enzyme conjugates: a new approach to cancer therapy , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  J. Bolin,et al.  Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate. , 1982, The Journal of biological chemistry.

[56]  D. Kessel,et al.  Uptake as a Determinant of Methotrexate Response in Mouse Leukemias , 1965, Science.

[57]  L. Matherly,et al.  Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. , 1991, Cancer research.

[58]  F. M. Huennekens,et al.  Inhibition of Dihydrofolic Reductase by Aminopterin and Amethopterin.∗ † , 1958, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[59]  F. M. Huennekens,et al.  Folic Acid Coenzymes , 1958, Science.

[60]  F. M. Huennekens,et al.  Increased Level of Dihydrofolic Reductase in Leucocytes of Patients Treated with Amethopterin , 1962, Nature.

[61]  Huennekens Fm.  The role of dihydrofolic reductase in the metabolism of one-carbon units. , 1963 .

[62]  C. Beddell,et al.  The structure of mouse L1210 dihydrofolate reductase‐drug complexes and the construction of a model of human enzyme , 1987, FEBS letters.

[63]  I. Pastan,et al.  Receptor-Mediated Endocytosis: General Considerations and Morphological Approaches , 1983 .

[64]  R. Mackenzie,et al.  NAD-dependent methylenetetrahydrofolate dehydrogenase is expressed by immortal cells. , 1985, The Journal of biological chemistry.

[65]  J. Montgomery,et al.  Carbon-13 nuclear magnetic resonance study of protonation of methotrexate and aminopterin bound to dihydrofolate reductase. , 1981, Biochemistry.

[66]  J. Dann,et al.  Nuclear magnetic resonance studies of the binding of substrate analogs and coenzyme to dihydrofolate reductase from Lactobacillus casei. , 1974, Biochemistry.

[67]  F. Winkler,et al.  Crystal structure of human dihydrofolate reductase complexed with folate. , 1988, European journal of biochemistry.

[68]  C. A. Nichol,et al.  On the Mechanism of Action of Aminopterin.∗ , 1950, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.